Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,594.80
(
-0.53%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
103.94
(
-0.47%
)
Bitcoin
70,633.42
(
1.05%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 193725

Friday, 07/31/2015 9:17:14 PM

Friday, July 31, 2015 9:17:14 PM

Post# of 257262
Re: AMGN’s threat from FoBs

http://www.wsj.com/articles/amgen-to-undergo-experimental-treatment-1438363128

At about 18 times forward earnings, Amgen stock isn’t especially pricey for a large biotech. But…for Amgen to maintain or grow its valuation, biosimilars need to arrive with a whimper, not a roar.

In 2Q15, 36% of AMGN’s product sales came from Epogen, Neupogen, and Neulasta, which are off-patent in the US and several other major countries.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now